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I 
N the past four years there has been an enormous increase in 
research involving basic fibroblast growth factor (FGF) t 
as a result of  the development  of  effective  methods for the 
isolation  of  the protein and the availability  of  characterized nu- 
cleic acid probes, specific antibodies, and recombinant growth 
factor. Several reviews have been published describing much 
of the basic biology of acidic FGF (aFGF) and basic FGF 
(bFGF) (5, 25, 33). Therefore, in this mini-review we have fo- 
cused on specific areas in bFGF biology  in which uncertainties 
exist. For simplicity, we have confined this review to bFGF. 
However, some of  the questions concerning bFGF also apply 
to aFGF and are discussed. 
History 
FGF was originally identified as an activity in extracts of pi- 
tuitary and brain that stimulated the growth of 3T3 cells (3, 
23). The activity was shown to be due to two proteins. One 
of them, aFGF, had an acidic pI (5.6) and eluted from hep- 
arin-Sepharose with I M NaC1 (34, 65). The second, bFGF, 
had a  basic pI  (>9.0),  eluted from heparin-Sepharose  at 
1.5 M NaCI, and had 55 % sequence homology to aFGF (14). 
The introduction of heparin-affinity chromatography facil- 
itated the isolation of sufficient quantities of bFGF for struc- 
tural studies. Bovine pituitary bFGF was found to be a 146- 
amino acid protein with a molecular weight of 16,400 (14), 
while human placental bFGF had 157 amino acids with a 
molecular weight of 17,500 (63). However, smaller forms of 
both bovine and human bFGF have been identified which ap- 
parently arise by truncation at the amino terminus (43).  The 
shortest molecule that retained biological activity lacked the 
first 15 amino acids present in bovine pituitary bFGF (14). 
In some instances these truncated forms of bFGF seem to be 
generated by proteases released during the isolation proce- 
dure (31). The 146-amino acid bovine bFGF may, itself, de- 
rive from a larger molecule since extraction of pituitaries in 
the presence of protease inhibitors yielded a  larger form 
(66).  This idea is supported by data on the potential transla- 
1. Abbreviations  used in this paper: aFGE acidic fibroblast growth factor; 
bFGE basic fibroblast  growth factor; ECM, extracellular matrix; FGE fibro- 
blast growth factor; GAG, glyeosaminoglyeans;  HSPG, heparan sulfate pro- 
teoglyeans. 
tion initiation sites identified from the eDNA for bFGF (see 
below). 
The amino acid sequence of bFGF has some unusual at- 
tributes, bFGF contains four cysteines. Two are conserved 
among all members of the FGF family (71) and may be im- 
portant in determining the tertiary structure of  bFGF through 
intramolecular disulfide bonds. The two remaining cysteines 
are not essential for biological activity (19). In recombinant 
bFGF produced in Escherichia cold, these two cysteines ap- 
pear to remain reduced (19). However, the two nonessential 
cysteines in natural bFGF may be involved in disulfide bonds 
with free cysteines since the initial amino acid analysis of  bo- 
vine pituitary bFGF yielded six cysteines (14). 
bFGF has two sequences (residues 18-22 and 107-110 of 
bovine pituitary bFGF) that have the characteristics of hepa- 
rin binding domains (14), and synthetic peptides that include 
these amino acid sequences bind heparin (6). However, pep- 
tides that include neighboring sequences also bind heparin 
(sometimes with a higher affinity) suggesting that the bepa- 
rin-binding activity is not restricted to simple domains (6). 
The protective effect of heparin against denaturation as well 
as proteolytic degradation of bFGF (24,  55, 62) indicates 
that significant  changes in the tertiary structure of  the protein 
must occur when it is complexed to this polysaccharide. The 
precise nature of the heparin-bFGF interactions remain to 
be characterized. 
Analysis of a genomic clone of human bFGF revealed that 
the bFGF gene is interrupted by at least two introns and 
spans over 40 kb (2). The human genome contains one copy 
of the bFGF gene located on chromosome 4 (35).  From two 
to five mRNA species that cross react with probes for bFGF 
have been described (1, 32) and differ in the length of their 
3' untranslated regions (32). 
Synthesis 
The biosynthesis of bFGF appears  to involve a  relatively 
unique mechanism. The bFGF first isolated from the bovine 
pituitary began with the amino acid sequence Pro-Ala-Leu- 
Pro (14). bFGFs from several other tissues and cell lines were 
also  isolated and characterized  shortly thereafter.  Amino 
acid sequence studies indicated that degradation could take 
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bFGF were found (see above).  When the bovine pituitary 
bFGF amino acid sequence was compared with the amino 
acid sequence predicted from the cloned bFGF cDNA,  a 
possible ATG (Met) initiation codon was found at position 
-9 from the CCC codon corresponding to the amino termi- 
nal Pro (1, 32). Therefore, this ATG codon was proposed as 
the initiation site for bFGF translation. However, amino acid 
sequencing of the placental form of human bFGF yielded a 
protein with an amino terminal sequence Gly-Thr-Met-Ala- 
Ala-Gly-Ser-Ile-Thr-Thr-Leu-Pro-Ala-Leu-Pro  which agreed 
with the sequence predicted from the cDNA and indicated 
that additional higher molecular mass forms of bFGF must 
exist (63).  Indeed, Moscatelli et al.  (42)  isolated a 25-kD 
form of bFGF from guinea pig brain. This protein was as ac- 
tive as 18 kD human bFGF, was cross reactive with antibod- 
ies to  18-kD  human bFGF (42),  and was extended at the 
amino terminal end (63a). Western blots and immunoprecip- 
itations from numerous cell lines always reveal bFGF forms 
with molecular weights of 24, 22.5, and 22 kD in addition 
to the 18-kD form (unpublished observations). These higher 
molecular mass forms are as abundant as the 18-kD  form, 
and pulse-chase data shows no conversion of the higher mo- 
lecular mass forms into the 18-kD form. The mechanism of 
generation of these higher molecular mass forms of bFGF 
is not obvious since no additional ATG codons occur in the 
cDNA 5' to the originally proposed ATG initiation codon. 
In an elegant series of experiments, Florkiewicz and Som- 
mer (16) have demonstrated translational initiation at CUG 
(Leu) codons 5' to the AUG (Met) codon. In COS cells trans- 
fected with cDNA in which the ATG codon was changed to 
GCT, only bFGF species with molecular masses of 22, 22.5, 
and 24 kD were formed. The insertion of a frame-shift muta- 
tion 5' to the ATG codon eliminated the synthesis of the 22-, 
22.5-, and 24-kD forms, while the specific mutation of the 
CTG codon -167 to -165 to CTT (Leu) resulted in the loss 
of the 24-kD form. Similar results were obtained by Prats et 
al. (48).  These results must be confirmed by additional pro- 
tein sequencing of the higher molecular mass forms. The bi- 
ological consequences of translation initiation at CUG and 
the synthesis of multiple forms of bFGF are not obvious 
but can be explored in cells stably transfected with unique 
cDNAs. Arg levels in the amino terminal extensions may be 
as high as 29 %. This may confer unique properties to these 
proteins. Unpublished observations (Renko, M., and D. B. 
Rifkin) on the suhcellular distribution of the 18-, 22-, 22.5-, 
and 24-kD forms of bFGF indicate that the forms are not 
equally distributed within subcellular compartments.  The 
18-kD  form is  primarily cytoplasmic, whereas  the other 
forms are not. Thus, the forms of bFGF may differ function- 
ally as well as structurally. Biological experiments demon- 
strating functional differences have not been described. 
Distribution 
bFGF has been found in all organs, solid tissues, tumors, and 
cultured cells examined (5,  25,  33).  Although bFGF was 
reported to be present in serum (38), the validity of the assay 
used has been questioned (21). It is unclear whether the ubiq- 
uitous distribution of bFGF in cultured cells represents its in 
vivo distribution.  In cultures of bovine endothelial cells, 
bFGF has autocrine activities which may be required for 
their maintenance (57).  Thus, the expression of bFGF may 
be an adaptive response that allows cell survival in culture. 
Clearly, the limited number of immunolocalization studies 
that have been published show a restricted distribution of the 
antigen in vivo (18, 26, 28), consistent with the conjecture 
that the wide-spread occurrence of bFGF in cultured cells 
may be artifactual. 
Biological Activities 
At the present time, the normal function(s) of bFGF is un- 
known. In vitro, the molecule displays a broad spectrum of 
activities on many types of  cells, including increased growth, 
induction of plasminogen activator, interstitial and type IV 
collagenase, and increased cell migration (25, 37, 41, 50). In 
vivo, the administration of exogenous bFGF induces a vari- 
ety of responses, bFGF causes a rapid neovascularization in 
the cornea, kidney capsule, or skin as well as fibroplasia in 
the dermis (9,  17, 27, 59), supporting the hypothesis that it 
is involved in neovascularization and wound repair. 
Perhaps,  the most intriguing role proposed for bFGF is 
that of an inducer during embryonic development. In 1979, 
Mescher and Gospodarowicz (36)  proposed that FGF en- 
hanced  limb  regeneration  in  amphibians.  More  recently, 
Slack et al. (61) observed that purified bFGF mimicked the 
mesenchymal inducer in Xenopus embryos. In these experi- 
ments, the application of purified bFGF to ectodermal ex- 
plants of early Xenopus embryos induced the differentiation 
of mesenchyme. In addition, when the animal and vegetal 
pole explants were separated by a nylon gauze, the inclusion 
of heparin in the assay blocked the normally observed induc- 
tion of mesoderm formation in the animal pole explant. The 
authors concluded that under these conditions binding to 
heparin blocked endogenous bFGF from interacting with its 
receptor. The reports that bFGF mRNA and protein are pres- 
ent in Xenopus oocytes and early embryos (30, 60) support 
the hypothesis that endogenous bFGF may act as an em- 
bryonic inducer. 
The major question which persists in studies with bFGF 
is whether results obtained after the addition of exogenous 
bFGF  represent  the  normal  role of this protein.  Several 
members of the FGF family may share a common receptor 
(see below), and the addition of  bFGF to a system which uses 
any of these proteins may induce a response. Since bFGF 
seems to be inefficiently  released by cells, its role in extracel- 
lular inductions during embryonic development or tissue 
proliferation is not obvious. One of the members of the FGF 
family that is secreted, such as hst/K-fgf or FGF-5 (see be- 
low), may be more suited to such a role. One approach to 
this problem is through the use of reagents, such as antibod- 
ies, to neutralize the activities of specific members of the 
FGF family. The ability of neutralizing antibodies to bFGF 
to block an endogenous in vivo process would be a powerful 
demonstration of a natural role for this growth factor.  This 
is a problem when considering the normal role of all growth 
factors and has only been answered successfully for nerve 
growth factor. 
Related Proteins 
bFGF is a member of a family of related proteins or gene 
products. In addition to aFGF (34), two other homologous 
proteins have been identified. The hst/K-fgf gene product is 
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bFGE The hst/K-fgf gene was identified by transfection as- 
says as an oncogene from a Kaposi's sarcoma (10) and in- 
dependently from a human stomach tumor (64). The protein 
is a potent mitogen for fibroblasts and endothelial cells, in- 
creases  the production of plasminogen activator by these 
cells and, like aFGF, is potentiated by heparin (11, 12). FGF-5, 
a 267-amino acid protein that is 43 % homologous to bFGF, 
was identified after transfection of NIH-3T3 cells with tumor 
cell DNA followed by selection in growth factor deficient 
medium (72). FGF-5 is mitogenic for both 3T3 and endothe- 
lial ceils and binds to heparin. The fifth member of the fam- 
ily is int-2 (13). The synthesis of int-2 mRNA is enhanced 
in MMTV-induced tumors, presumably as a result of the in- 
tegration of the virus adjacent to the int-2 gene and increased 
transcription driven by the viral promoter. The protein en- 
coded by int-2 mRNA has not been isolated, but the pre- 
dicted sequence has a 44% homology to bFGE When com- 
pared with bFGF, both the int-2 and FGF-5 proteins contain 
extensions at their carboxy-terminal ends, while hst/K-fgf 
has an extension at its amino terminal end. Both hst/K-fgf 
and FGF-5 are initially translated with hydrophobic signal 
sequences and are secreted into the culture medium of trans- 
fected cells. A classic signal sequence does not appear to be 
present in the predicted int-2 translation product. In this re- 
spect int-2 resembles bFGF and aFGF. While the expression 
of these bFGF-related proteins has been studied primarily in 
tumor cells, it is reasonable to expect that synthesis in nor- 
mal  cells  will  be  found.  The  regulation  of hst/K-fgf in 
differentiating teratocarcinoma cells  (67)  and int-2  in the 
mouse embryo (70)  indicates that the expression of these 
proteins may be required for specific developmental events, 
but this remains to be definitively proven. 
Transforming Potential 
Within the past year, several papers have appeared demon- 
strating that high expression of 18-kD bFGF in NIH-3T3 (8, 
53), BALB/c 3T3 (56), or BHK-21 (46) cells yields a trans- 
formed phenotype. Rogelj et al. (53) were the first to demon- 
strate that transfection of NIH-3T3 cells with bFGF expres- 
sion vectors yielded transformed cells. They found, however, 
that transformation occurred only with a bFGF construct that 
contained the immunoglobulin signal sequence fused 5' to 
the  bFGF  coding  sequence.  Transfection with  constructs 
coding only for bFGF  yielded no transformants.  Similar 
results were observed by Blam et al. (8) using a bFGF cDNA 
fused to the growth hormone signal sequence cDNA. Other 
groups observed growth in low serum, increased saturation 
density, and growth in soft agar with cells transfected with 
bFGF expression constructs lacking a signal sequence (46, 
51, 56). Interestingly, in no instance was >1% of the 18-kD 
bFGF found in the culture medium, even in the transfectants 
studied by Rogelj et al. (53). In these experiments, the inclu- 
sion in the medium of neutralizing antibodies to bFGF had 
no effect on the phenotype with the exception of the study 
of Sasada et al. (56) in which a small alteration in morphol- 
ogy and a  decrease in growth in soft agar was observed. 
Thus, transformation by bFGF may result from the protein 
acting intracellularly as described for the sis oncogene (7) 
or from extracellular protein which cannot be neutralized by 
antibody. 
bFGF does not appear to be a potent transforming factor, 
however. The amount of bFGF produced in transformants is 
quite high and may approach 0.1% of the total cellular pro- 
tein. The amount of bFGF synthesized by transfectants also 
appears to correlate directly with the phenotype of the cell, 
with low producers having a nontransformed morphology and 
high producers having a  transformed morphology (51). A 
comparison of the amounts of bFGF and hst/K-fgf required 
to  transform NIH-3T3  cells  revealed that  10-100x  more 
bFGF than hst/K-fgf was necessary (51). This may relate to 
the fact that hst/K-fgf is a secreted protein and is efficiently 
released, while bFGF is not. Therefore, the differences ob- 
served by various groups in the transforming potential of 
bFGF may reflect differences in expression levels. Constructs 
without a signal sequence will transform only when expressed 
at high levels, while constructs with a signal sequence can 
transform at lower levels of expression. Thus, it is unlikely 
that enhanced bFGF expression is a primary event in the eti- 
ology of natural tumors since sufficient levels of expression 
would be difficult to achieve. 
Receptors 
Receptors for bFGF have been identified on a variety of cul- 
tured cells (39, 44, 47). Binding affinity for bFGF has been 
estimated to be 2  x  10-" M to 2  x  10  -I° M. The number 
of receptors per cell ranges from ,,,3,000 per cell for bovine 
aortic endothelial cells (unpublished observations) to 80,000 
per cell for BHK cells (44). There seems to be an approxi- 
mate inverse relationship between the number of receptors 
per cell and the content of endogenous bFGF (39), suggest- 
ing that receptors are down-regulated by endogenous growth 
factor.  Chemical cross-linking of labeled bFGF to cell sur- 
face proteins has identified two putative receptors with mo- 
lecular weights of 125,000  and  145,000.  The relationship 
between the two species of receptor is presently not under- 
stood. 
Receptors for aFGF also have been identified on a variety 
of cells (20, 29). bFGF will compete for the binding of aFGF 
to its receptors, and aFGF will compete for the binding of 
bFGF to its receptors (45, 47). These results suggest that the 
two molecules share receptors,  although there is evidence that 
the 145-kD receptor has a stronger affinity of bFGF, while 
the 125-kD  recepto  r has a stronger affinity for aFGF (45). 
Recent work indicates that a third member of the FGF fam- 
ily, the hst/K-fgf protein, also shares receptors with bFGF 
(Newman, K. M., and D. Moscatelli, unpublished observa- 
tions). These results suggest that the members of the FGF 
family may have overlapping affinities for the FGF receptors. 
Release 
Considerations of the action of bFGF must be tempered by 
the fact that the mechanism for its release is not understood. 
This is also true for aFGF as well as interleukin-1.  All of the 
translational products of bFGF mRNA appear to lack a sig- 
nal sequence which would direct their release via the normal 
secretory pathway. The first nine amino acids in the 18-kD 
form of bFGF, which were missing from the original isolates 
of  bovine bFGF and are slightly hydrophobic, have been sug- 
gested to function as a signal (1). However, this sequence is 
probably too short to act as a  classical signal in vectorial 
translation. While a few reports have described the occur- 
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tions have always been so low that release by cell death can- 
not be excluded. 
Soluble extracellular bFGF may always be present at low 
concentrations,  however,  since  neutralizing  antibodies  to 
bFGF alter several in vitro cellular properties. These include 
cell morphology, plasminogen activator synthesis, cell mi- 
gration, and growth in soft agar (56, 57). These results indi- 
cate that bFGF may act as an autocrine or paracrine factor. 
While the possibility that the neutralizing antibodies react 
with a second uncharacterized antigen that shares an epitope 
with bFGF and controls the phenomena studied has not been 
rigorously eliminated, the simplest explanation of these ob- 
servations is via released bFGE However, no defined mecha- 
nism for release has been described other than cell death. 
Whether this is the only mechanism for release is one of the 
more important questions in FGF biology. 
Matrix Interactions 
The strong interaction of bFGF with heparin probably re- 
flects an in vivo affinity of bFGF for extracellular matrix 
(ECM) heparan sulfate proteoglycans (HSPG) and glycos- 
aminoglycans (GAG) (55,  68).  Several groups have shown 
that bFGF is found in the ECM (4, 18, 69). In this state, the 
growth factor appears to be bound to HSPG since it is solubi- 
lized by heparinase treatment (69). While the overall binding 
of bFGF to HSPG is not as strong as to heparin, subspecies 
of HSPG exist with binding affinities for bFGF equal to that 
of heparin (55).  Immunohistochemical staining of basement 
membranes such as Descemet's membrane has revealed the 
presence of bFGF in these structures (18) indicating that 
bFGF may be.concentrated in the ECM in vivo as well as 
in vitro. 
The biological significance of this interaction is not clear, 
but several roles for the bFGF-HSPG interaction have been 
suggested. Folkman et al. (18) and Vlodovsky et al. (69) have 
proposed that bFGF may be  stored in these extracellular 
structures and mobilized when needed by remodeling of the 
basement membrane or ECM through the production of hy- 
drolases.  Moscatelli (39,  40)  has shown that exogenously 
added bFGF equilibrates between matrix binding sites and 
plasma membrane receptors and that removal of bFGF from 
its high affinity receptor with low pH results in a reequilibra- 
tion ofbFGF from the matrix with the receptor. Thus, matrix 
binding of bFGF may provide a reservoir of growth factor. 
In a recent series of experiments, Presta et al.  (49)  and 
Flaumenhaft et al. (15) demonstrated that the extended ac- 
tion of bFGF on the production of plasminogen activator by 
endothelial cells after a brief exposure to growth factor re- 
quires the presence of matrix-bound bFGE  Both of these 
groups observed that transient (10-60 min) exposure of cells 
to growth factor resulted in long term stimulation of plasmin- 
ogen activator production if the bFGF was simply removed 
from the cultures by washing with PBS.  However,  if the 
growth factor was removed by conditions that stripped bFGF 
from the ECM, no stimulation of protease activity was ob- 
served.  These observations were interpreted as indicating 
that the matrix-bound bFGF provides a continuous source of 
ligand for the bFGF receptor and that continuous occupancy 
of the receptor is required for long term (24-h)  stimulation. 
Similar results were obtained when DNA synthesis was mea- 
sured after a brief exposure of cells to bFGF (15). 
Gospodarowicz  and Cheng  (24) demonstrated  that the 
interaction of bFGF with heparin stabilizes  the protein to 
thermal denaturation and extremes of pH. When bFGF is 
bound to  either  heparin  or  heparan sulfate,  it  is  also  protected 
against  degradation by trypsin  or plasrnin  (55,  62). Heparin 
has also  been shown to  protect  aFGF from plasrnin  degrada- 
tion  (54).  Heparin interaction  may be important in stabiliz- 
ing bFGF to proteases  generated during wound healing  and 
tumor growth: processes in which bFGF may play  a role. 
Vlodavsky et al. (69) have shown that  bFGF can be re- 
leased from the ECM  by the action of heparinasc, while 
Saksela and Rifkin (unpublished observations) have found 
that  plasmin releases  bFGF complcxed to  HSPG or  GAG. In 
the case of  plasmin, the bFGF is released  as a noncovalent 
complex of bFGF  and HSPG-GAG.  bFGF  complexed to 
heparin or HSPG  appears to interact  with its  receptor  in an 
identical  manner to free  bFGF (39, 55). Since both hepa- 
rinase  and plasmin may be present  at  sites  of  tissue  remodel- 
ing or growth, they  may afford  a mechanism for enhanced 
bFGF release.  A question that  remains is  what are the rela- 
tive contributions of hcparinase and plasmin to bFGF  re- 
lease. 
These studies  have suggested  the  following  model for  bFGF 
interaction  with cells  and  matrix.  Upon release  from the  cell, 
the growth factor  binds to HSPG. The bFGF bound to the 
matrix may be mobilized either  by hcparinase or  by plasmin 
and is  released  as  a  complex of  either  bFGF-HSPG  or  bFGF- 
GAG. This  complex is  capable  of  diffusing  through the  stroma 
to the target  cells  and binding to the high affinity  plasma 
membrane  receptor.  This model has several  attractive  fea- 
tures.  It  provides  for  a  constant  cxtracellular  source of  bFGF 
under conditions  where the initial  release  of  the  growth fac- 
tor  may be  as  a  bolus  after  cell  death.  The solubilization  from 
the ECM  of  bFGF as a complex with HSPG or GAG yields 
a form of  bFGF that  is  stable  to  denaturation  and proteolytic 
degradation. The bFGF-HSPG  or bFGF-GAG  should dif- 
fuse  away from the  matrix more readily  than  free  bFGF since 
bFGF-hcparin or  bFGF-HSPG  complexes do not  bind to  the 
ECM  (39,  55). While the biological  significance  of bFGF- 
matrix interactions  remains to be proven, a functional  re- 
quirement for interaction  with matrix may exist  for other 
growth factors.  For example, two recent reports  describe a 
role  of HSPG  in localizing  colony-stimulating  factors  to the 
stromal cell  matrix where interaction  with stem cells  occurs 
(22, 52). 
Conclusions 
In this review we have described a number of the features of 
bFGF. We have focused on specific aspects of bFGF biology 
that are  of particular interest,  bFGF has  several  unusual 
properties not associated with other growth factors that indi- 
cate that it must act in a unique fashion. Foremost among 
these is its lack of a signal sequence and intracellular local- 
ization. The intracellular localization of this growth factor 
raises questions concerning how and when bFGF is released. 
Moreover, the existence of hst/K-fgf  and FGF-5 suggests that 
processes requiring a secreted molecule with FGF-like activ- 
ity may use one of these factors and that bFGF has a different 
function. Thus, the lack of a signal sequence may be crucial 
to the specific biological role of bFGE The generation of 
multiple forms of  bFGF through translation initiation at both 
CUG and AUG codons is highly unusual and implies that the 
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nally, the strong interaction ofbFGF with matrix HSPG may 
be indicative of a novel type of extracellular functional con- 
trol which has not been described for other growth factors. 
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